Skip to content. | Skip to navigation

Personal tools
Log in

Navigation

You are here: Home / Projects / Discovery of new drug candidates for the clinical management of prostate cancer

Discovery of new drug candidates for the clinical management of prostate cancer

Our aim is to identify small molecules that may prevent or delay the progression of prostate cancer towards androgen-independent disease.

Project Leaders Marianne Sadar
Project Co-Investigators Raymond Andersen, Yikan Wang
Involved Organizations
Canada's Michael Smith Genome Science Centre
University of British Columbia
British Columbia Cancer Agency
Funding Agencies
Device for screening the effect of thousands of compounds on prostate cancer cell cultures.

Screening Robot

Overview

The goal of this research has been to screen and then test small molecules that may prevent or delay the progression of prostate cancer to androgen-independence. In the course of this work we have identified important lead compounds with potential to be used to develop new drugs that will delay or prevent the development of androgen independent prostate cancer.

    Specific aims:
  1. Screen several small molecule libraries using a cell-based system to identify lead compounds or extracts that inhibit transactivation of N-terminus of the AR (androgen receptor)
  2. Isolate the pure active compound from the extracts
  3. Validate the lead compound by application of secondary screens
  4. Employ xenograft models and test whether the small molecules that inhibit activation of the androgen receptor in vitro have any effect on these tumors

 

Recent Publications by our Research Team:

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, BaƱuelos CA, Williams DE, McEwan IJ, Wang Y, Sadar MD..Cancer Cell. 2010 Jun 15;17(6):535-46.

Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells.Sadar MD, Williams DE, Mawji NR, Patrick BO, Wikanta T, Chasanah E, Irianto HE, Soest RV, Andersen RJ.Org Lett. 2008 Nov 6;10(21):4947-50.

Contact Information

For all project related inquires please contact us.

Joanne Johnson, Project Manager
Genome Sciences Centre, BC Cancer Agency
Email: jjohnson@bcgsc.ca
Phone: 604-675-8000 x 7901
Fax: 604-675-8178